Cargando…

Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib

Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been establishe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hua-fei, Zhang, Qu-xia, Zhu, You-cai, Du, Kai-qi, Li, Xiao-feng, Wu, Li-xin, Wang, Wen-xian, Xu, Chun-wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225853/
https://www.ncbi.nlm.nih.gov/pubmed/30464529
http://dx.doi.org/10.2147/OTT.S178985
_version_ 1783369864097824768
author Chen, Hua-fei
Zhang, Qu-xia
Zhu, You-cai
Du, Kai-qi
Li, Xiao-feng
Wu, Li-xin
Wang, Wen-xian
Xu, Chun-wei
author_facet Chen, Hua-fei
Zhang, Qu-xia
Zhu, You-cai
Du, Kai-qi
Li, Xiao-feng
Wu, Li-xin
Wang, Wen-xian
Xu, Chun-wei
author_sort Chen, Hua-fei
collection PubMed
description Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been established. A 69-year-old Chinese man presented for evaluation of a tumor in the right lower lung and mediastinal lymph node enlargement on clinical examination. The clinical stage was cT(2)N(2)M(0) (stage IIIA). Histologic examination of the tumor revealed lung adenocarcinoma. He could not tolerate surgery; hence, he received two chemotherapy regimens. However, the disease progressed. He had bloating after chemotherapy and decreased flatus. An abdominal CT scan showed an intestinal effusion with local intestinal obstruction. Medical treatment was ineffective; hence, he underwent a diagnostic laparoscopy. The pathologic evaluation suggested an intestinal metastatic adenocarcinoma from the primary lung cancer. Based on an real-time PCR assay, the tumor had a ROS1 fusion and responded well to crizotinib. The progression-free survival was 7 months. Physicians must be aware of the possibility of intestinal metastases from primary lung cancer. With an accurate diagnosis and thorough evaluation, patients may benefit from targeted therapy.
format Online
Article
Text
id pubmed-6225853
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62258532018-11-21 Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib Chen, Hua-fei Zhang, Qu-xia Zhu, You-cai Du, Kai-qi Li, Xiao-feng Wu, Li-xin Wang, Wen-xian Xu, Chun-wei Onco Targets Ther Case Report Small intestinal metastases from primary lung cancer are rare. Such patients have a poor prognosis. Early diagnosis of small intestinal metastases is difficult because of the low incidence of clinically apparent symptoms. The standard treatment for small intestinal metastases has not been established. A 69-year-old Chinese man presented for evaluation of a tumor in the right lower lung and mediastinal lymph node enlargement on clinical examination. The clinical stage was cT(2)N(2)M(0) (stage IIIA). Histologic examination of the tumor revealed lung adenocarcinoma. He could not tolerate surgery; hence, he received two chemotherapy regimens. However, the disease progressed. He had bloating after chemotherapy and decreased flatus. An abdominal CT scan showed an intestinal effusion with local intestinal obstruction. Medical treatment was ineffective; hence, he underwent a diagnostic laparoscopy. The pathologic evaluation suggested an intestinal metastatic adenocarcinoma from the primary lung cancer. Based on an real-time PCR assay, the tumor had a ROS1 fusion and responded well to crizotinib. The progression-free survival was 7 months. Physicians must be aware of the possibility of intestinal metastases from primary lung cancer. With an accurate diagnosis and thorough evaluation, patients may benefit from targeted therapy. Dove Medical Press 2018-11-05 /pmc/articles/PMC6225853/ /pubmed/30464529 http://dx.doi.org/10.2147/OTT.S178985 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Case Report
Chen, Hua-fei
Zhang, Qu-xia
Zhu, You-cai
Du, Kai-qi
Li, Xiao-feng
Wu, Li-xin
Wang, Wen-xian
Xu, Chun-wei
Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
title Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
title_full Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
title_fullStr Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
title_full_unstemmed Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
title_short Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
title_sort intestinal metastasis from primary ros1-positive lung adenocarcinoma cancer patients responding to crizotinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225853/
https://www.ncbi.nlm.nih.gov/pubmed/30464529
http://dx.doi.org/10.2147/OTT.S178985
work_keys_str_mv AT chenhuafei intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT zhangquxia intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT zhuyoucai intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT dukaiqi intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT lixiaofeng intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT wulixin intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT wangwenxian intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib
AT xuchunwei intestinalmetastasisfromprimaryros1positivelungadenocarcinomacancerpatientsrespondingtocrizotinib